If you have been reading about reconstitution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Lyophilised storage | −20 °C, dry, protected from light | Vials are sealed and allowed to reach room temperature before opening |
| Reconstituted storage | 2 to 8 °C, protected from light | Short-term holding; avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Water for injection or bacteriostatic water | Added slowly along the vial wall to reduce foaming and shear |
| Purity measurement | RP-HPLC with area normalisation | Acetonitrile-water gradient monitored at roughly 214 nm |
| Identity confirmation | Electrospray ionisation mass spectrometry | Observed mass compared against the calculated peptide mass |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
== Target == It seems likely that TsPep2 has inhibitory actions on potassium channels, based on its sequence similarities in the C-terminal beta sheet with the potassium channel inhibitory alpha family (α-KTX) and on its similarities in the patterns of disulfide bridges with other short scorpion venom toxins.
Impetigo herpetiformis Intrahepatic cholestasis of pregnancy (cholestasis of pregnancy, jaundice of pregnancy, obstetric cholestasis, prurigo gravidarum) Linea nigra Pemphigoid gestationis (gestational pemphigoid, herpes gestationis) Prurigo gestationis (Besnier prurigo, early-onset prurigo of pregnancy, linear IgM dermatosis of pregnancy, papular dermatitis of pregnancy, prurigo of pregnancy, Spangler's papular dermatitis of pregnancy) Pruritic folliculitis of pregnancy Pruritic urticarial papules and plaques of pregnancy (late-onset prurigo of pregnancy, polymorphic eruption of pregnancy, PUPPP syndrome, toxemic rash of pregnancy, toxic erythema of pregnancy) Striae gravidarum
==== Prevalence of medical diagnosis ==== In a study published in 2016, based on US health insurance claims data, out of 19,833,939 US males aged ≥18 years, only 1,108,842 (5.6%), were medically diagnosed with erectile dysfunction or on a PDE5I prescription (μ age 55.2 years, σ 11.2 years). Prevalence of diagnosis or prescription was the highest for age group 60–69 at 11.5%, lowest for age group 18–29 at 0.4%, and 2.1% for 30–39, 5.7% for 40–49, 10% for 50–59, 11% for 70–79, 4.6% for 80–89, 0.9% for ≥90, respectively.
Actually, some manufacturers of high-throughput systems have adopted the system to work with their robots. This illustrates the orientation of this kit solution to laboratories with a larger number of samples.
Mechano growth factor (MGF, IGF-IEc) is a naturally occurring 24-amino acid peptide which is the C-terminal fragment derived from enzymatic cleavage of insulin-like growth factor 1 (IGF-1). It is expressed during muscle repair following physical activity, and has anabolic effects. This has led to illicit use by athletes leading to MGF being banned by the World Anti-Doping Association. At least one research paper raised concerns about the potential carcinogenicity of this compound.
Sources: en.wikipedia.org
Three prime untranslated regions (3′UTRs) of messenger RNAs (mRNAs) often contain regulatory sequences that post-transcriptionally influence gene expression. Such 3′-UTRs often contain both binding sites for microRNAs (miRNAs) as well as for regulatory proteins. By binding to specific sites within the 3′-UTR, miRNAs can decrease gene expression of various mRNAs by either inhibiting translation or directly causing degradation of the transcript. The 3′-UTR also may have silencer regions that bind repressor proteins that inhibit the expression of a mRNA. The 3′-UTR often contains microRNA response elements (MREs). MREs are sequences to which miRNAs bind. These are prevalent motifs within 3′-UTRs. Among all regulatory motifs within the 3′-UTRs (e.g. including silencer regions), MREs make up about half of the motifs. As of 2014, the miRBase web site, an archive of miRNA sequences and annotations, listed 28,645 entries in 233 biologic species. Of these, 1,881 miRNAs were in annotated human miRNA loci. miRNAs were predicted to have an average of about four hundred target mRNAs (affecting expression of several hundred genes). Friedman et al. estimate that >45,000 miRNA target sites within human mRNA 3′UTRs are conserved above background levels, and >60% of human protein-coding genes have been under selective pressure to maintain pairing to miRNAs. Direct experiments show that a single miRNA can reduce the stability of hundreds of unique mRNAs.
=== Liquid biomolecular condensates === Liquid–liquid phase separation (LLPS) generates a subtype of colloid known as an emulsion that can coalesce to form large droplets within a liquid. Ordering of molecules during liquid–liquid phase separation can generate liquid crystals rather than emulsions. In cells, LLPS produces a liquid subclass of biomolecular condensate that can behave as either an emulsion or liquid crystal. The term biomolecular condensates was introduced in the context of intracellular assemblies as a convenient but non-exclusionary term to describe non-stoichiometric assemblies of biomolecules. The choice of language here is specific and important. It has been proposed that many biomolecular condensates form through liquid–liquid phase separation (LLPS) to form colloidal emulsions or liquid crystals in living organisms, as opposed to liquid–solid phase separation to form crystals/aggregates in gels, sols or suspensions within cells or extracellular secretions. However, unequivocally demonstrating that a cellular body forms through liquid–liquid phase separation is challenging, because different material states (liquid vs. gel vs. solid) are not always easy to distinguish in living cells. The term "biomolecular condensate" directly addresses this challenge by making no assumption regarding either the physical mechanism through which assembly is achieved, nor the material state of the resulting assembly.
49 Squadron RAF in October 1956 in Operation Buffalo at Maralinga; Project Dazzle and its research on re-entry vehicles enabled the Mercury-Atlas 6 launch to happen in February 1962; the Australian government built four launch pads for the Blue Streak in 1959, but it was cancelled in 1960, the redesignated satellite launcher Blue Streak first launched on 5 June 1964, and satellites would be launched by 1966, but only WRESAT was launched in November 1967, on a Redstone rocket instead; Woomera launched over 4000 missiles and cost the Australian government £900m; the site was demolished by the Australian government at the end of the 1960s; part of the former site is now the secret Joint Defense Facility Nurrungar 17 September Not in the Stars, making mathematical models for predictions; Robert May, Baron May of Oxford of Imperial College; William Phillips and his 1949 MONIAC economic model; a British Airways 747 flight simulator; computer models of epidemics - the R number, and vaccination policies; the UK fishing industry had quotas imposed in 1983, due to mathematical models of fish stocks; John Shepherd of the Centre for Environment, Fisheries and Aquaculture Science (CEFAS) laboratory in Lowestoft; computer models of warfare were developed by the Defence Operational Analysis Establishment in West Byfleet with deputy director David Faddy, which closed six years later, superseded in function by CORDA (UK); Irving Mintzer of the World Resources Institute; the NASA Goddard Space Flight Center had developed computer models of the Earth's atmosphere, such as rainfall; the hole in the Ozone layer and phytoplankton, with Norman Myers; Ian Riley of the Economist Intelligence Unit. Narrated by Bob Peck. Written, produced and directed by Chris Haws, made by InCA 24 September Race for the Top, CERN versus Fermilab; in 1983 CERN discovered the W and Z bosons, it and Fermilab were looking for the top quark; Leon M. Lederman, director of Fermilab; Andy Parker of CERN; CERN had 80 scientists led by Luigi Di Lella on its UA2 experiment, and Fermilab had its Collider Detector at Fermilab (CDF); Roy Schwitters; Fermilab had discovered the bottom quark in 1977; John Ellis of CERN; each team prepared for an annual physics conference at La Thuile, Aosta Valley in north-west Italy; UA2 had a meeting in July 1989 in Cambridge; the top quark would be discovered in 1995 with 175 GeV by Fermilab. Narrated by Carole Boyd, known for playing Lynda Snell in The Archers, joint production InCA and WGBH 1 October Walk on Wheels, a half-million disabled people have a wheelchair in the UK; NHS wheelchairs were made by Carter's; the quick-release axle was developed in World War II, for releasing munitions; the residential Treloar School in Alton, Hampshire, which was funded by individual LEAs, with charity funding as well; Bill Walmsley of the Department of Health's wheelchair research centre in Blackpool, now part of the Disability and Carers Service at DWP Peel Park at the end of the M55 motorway, on the A5230 in Westby-with-Plumptons. Narrated by John Hedges, produced by Jeremy Llewellyn-Jones, made by Chrysalis Television (North One Television) 8 October Invasion of the Body Scanners, a reference to the 1956 film Invasion of the Body Snatchers; X-rays were introduced in the 1890s, but it took fifty years to vastly improve the early crude techniques; CT was invented in the late 1960s - its inventor with Prince Philip, Duke of Edinburgh; Ian McDougall at a magnet technology company, who designed the first magnet, cooled with liquid helium in 1979; X-ray scans were a fairly crude process, but other types required computer image processing; Michael Boswell of GE Medical Systems; scans were taken in the coronal plane and sagittal plane; by 1989 the NHS only had four of these scanners - one was at Frenchay Hospital, made by GEC Medical (Picker International) - there were around 25 scanners in the whole UK; the Brockton Hospital; there were 1500 scanners in the US, with 39 in Massachusetts; Donald Longmore of the National Heart and Chest Hospitals, who performed the UK's first heart transplant on 3 May 1968; CT scanning had been performed for neuroradiology since the mid-1970s; radiology at Middlesex Hospital; medical ultrasound was a much safer technique than X-rays, and a new type deployed the Doppler effect, but medical ultrasound lacked cast-iron image definition; but scanners were hideously expensive, due to the convoluted enormous magnets that were required. Narrated by John Benson, produced by Mike Johnstone, directed by Ed Newstead, made by VATV (Video Arts) 15 October Wheels of War, about the early 1990s Leyland 4-tonne truck and defence procurement; James Adams, journalist; military historian Correlli Barnett; general service (GS) cargo vehicles, and a RE vehicle carrying a Medium Girder Bridge; a youthful-looking Mark Francois; the Austin Champ, designed in the 1950s; the British Aerospace Nimrod AEW3 was cancelled in 1986 at a cost of £860m; cost-plus contracts were replaced by competitive; Sir Peter Levine was brought in as Chief of Defence Procurement; the Leyland 4-tonne truck would replace the Bedford MK, made by Bedford Vehicles; journalist John Parsons; each vehicle would cost around £23,000 each; the Leyland 5-tonne was developed from its Comet and Roadrunner vehicles (developed into the DAF LF) under project director Stuart Hayes; the equivalent German vehicle, the MAN KAT1, had cost £75,000 each; the Panavia Tornado; Leyland design engineer Colin Ingram; the three vehicle prototypes were punishingly tested at the Royal Armament Research and Development Establishment (RARDE). Narrated by Anthony Valentine, produced by Patrick Uden made by Uden Associates 22 October Three Score Years and Then? 29 October Robotopia, advances of robotics in Japan, and bizarre contraptions; Frederik L. Schodt, author of the 1988 book Inside the Robot Kingdom - for hundreds of years until 1853, Japan was a fairly backward country; Joseph Engelberger, who developed the first industrial robot, Unimate, made by his company Unimation from 1961 - there were around 200,000 industrial robots, with around 130,000 of those in Japan; Japanese robot artist Hajime Sorayama, who drew lurid female robots; automated mannequins; nineteen universities in Japan were developing ungainly humanoid robots, notably Ichiro Kato at Waseda University; Seiuemon Inaba of FANUC, produced by Mike Wallington, made by Kai Productions 5 November Fly-by-wire, the new Airbus 320; software engineer Mike Hennell of the University of Liverpool; Roger Beteille, managing director of Airbus from 1967–85, and Henri Ziegler; John Knight of the University of Virginia; software engineer Bev Littlewood of City University; the A320 was the first fly-by-wire airliner; Blind Landing Experimental Unit testing at RAE Bedford in the 1960s, and developing the automatic pilot with a Vickers Valetta; testing Concorde in a wind tunnel; the Apollo project had depended on computers - it couldn't be done otherwise; Paul Ceruzzi of the Air and Space Museum; Philip Felleman of the Draper Laboratory; testing the F-16 in the early 1970s; Joe Sutter, head of Boeing from 1981–86; Boeing introduced flight management systems, so not needing a flight engineer; David Learmount of Flight International, and how Airbus had more commercial need to be innovative; the A300 was the first two-engined wide body aircraft; the A310 had electrical hydraulics and electronic control of some flight surfaces; John Cullyer of the University of Warwick; the A320 had five master computers; Gordon Corps, the Airbus test pilot, later to fly on Thai Airways International Flight 311 in 1992; Gilles Pichon, chief engineer of the A320; Jacques Troyes, head of Flight Control at Airbus; there was emergency mechanical control to the rudder and tail trim; the June 1988 Air France Flight 296Q - Michel Asseline, the pilot, said the aircraft had tried to land, when he tried to raise the aircraft; Alain Monnier of the DGAC said it was pilot error; Greg Holt of the FAA and Brian Perry of the CAA; the four-engined A330 would be manufactured from 1992; a prototype fly-by-wire relaxed stability Saab JAS 39 Gripen tumbles on 2 February 1989 at Linköping/Saab Airport, piloted by Lars Rådeström. Narrated by James Bellini, produced by Ben Shephard (historian), directed by John Longley, made by Box Television with WGBH 12 November Deadly Force, aerial shots of Miami; the WINZ Miami broadcaster; the Miami SWAT response team; the 1980 Miami riots; Sgt Louis Battle, Bernie Gonzalez and the Heckler & Koch MP5; Tom Salerno and the Remington Model 870 pump action shotgun, the M1911 pistol and Beretta M9; Ted Bradley; a WSVN news broadcast with Jane Akre; two thirds of Miami's population were Latin-American, and had many exiled citizens; the 1980 Mariel boatlift, from Cuba, added to the population and much to the crime; Miami had two murders a day in the 1980s; Robert Waller; Edna Buchanan of the Miami Herald; severed limbs washed up on Miami beach; the Colt Python; the Beretta 92; the Colt AR-15 semi-automatic rifle; 80% of SWAT call-outs were connected to the drug trade; two thirds of illegal drugs went through Miami; Sgt Louis Philips and negotiation techniques; SWAT negotiator Eric Caspener; 95% of SWAT negotiations work. Produced by David Jones, directed by Catherine Bailey, made by Buffalo Pictures 19 November Faster than a Speeding Bullet, and the quest for supersonic flight, eventually resulting in Concorde. The programme features former Concorde pilot Christopher Orlebar, who wrote The Concorde Story. The history of supersonic research dates back to the 18th Century, but supersonic flight only became achievable after the development of the jet engine. Featured aircraft include: the wartime Messerschmitt Me 262; the innovative de Havilland DH 108; the Messerschmitt Me 163 Komet; the Fairey Delta 2, the Bell X1 and numerous experimental "X Planes". After the war, the world's fastest non-experimental aircraft was the Lockheed SR-71 Blackbird, which could fly at 95,000 ft at 2,300 mph. The programme interviews key figures in the development of supersonic military aircraft and second generation SST (Supersonic Transport) aircraft. Narrated by Tony Anholt, written, produced and directed by Chris Haws, made by InCA
Darshan Ranganathan (4 June 1941 – 4 June 2001) was an organic chemist from India who was known for her work in bio-organic chemistry, including "pioneering work in protein folding." She was also recognized for her work in "supramolecular assemblies, molecular design, chemical simulation of key biological processes, synthesis of functional hybrid peptides and synthesis of nanotubes."
== Side effects == Side effects of etifoxine include slight drowsiness and headache. Rarely, etifoxine can cause benign skin eruptions or rashes and allergic reactions such as hives and angioedema. Etifoxine shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines. No cases of misuse or dependence with etifoxine were identified in a French pharmacovigilance survey, which is also in contrast to benzodiazepines. Etifoxine has been associated rarely with cases of severe dermal toxicity and liver toxicity. Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. A 2012 review of etifoxine by the French National Pharmacovigilance Committee determined that etifoxine was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics. The committee found (for a ten-year pharmacovigilance period) that safety concerns were rare or very rare and that the incidence of idiosyncratic hepatic (liver) problems were very rare.
Sources: en.wikipedia.org
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.
Liquid chromatography coupled to mass spectrometry is the most common approach because it combines a retention time with a mass measurement. A chromatographic peak alone cannot establish which peptide is present, so mass determination or amino acid analysis is used as an orthogonal confirmation alongside the separation.
This depends on buffer, pH, and concentration, and published stability data for this peptide are limited. In practice laboratories work through a refrigerated solution within a few weeks and discard samples that show cloudiness or visible particles. Freezing and thawing repeatedly is generally discouraged.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.